Thanks to the detection of EGFR gene alterations and ALK-rearrangements (10–30 and 3–7% of patients, respectively) and other driver mutations critical for lung cancer tumorigenesis and promotion, we have entered a new era of personalized therapy in the treatment of lung cancer patients driven by genotyping [10–12]. This evidence concerns the gene ALK and lung cancer.